ada guidelines dpp4 and glp-1 Adjusting Background Therapy when Initiating Receptor Agonists: What Pharmacists Need to Know (Module #2) GLP-1 analogues and DPP-4 inhibitors

Introduction Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes (T2DM), with a relevant impact on the economic costs for health care systems and on the quality of life for many patients (1, 2)

Moreover, IGF-1 boosts bone healing and increases movement in patients with tibia and hip fractures [2]

The intention-to-treat analysis showed no dementia risk difference between GLP1 receptor agonist and DPP4 inhibitor initiation

Unlike fillers that add volume, these treatments use microdoses of hyaluronic acid (HA) and other skin-loving ingredients to deeply hydrate, smooth fine lines, and improve elasticity

Findings presented at the Clinical Trials on Alzheimers Disease 2025 Congress in San Diego in December 2025 from the EVOKE and EVOKE+ Phase III studies evaluating oral semaglutide in early Alzheimers disease did not meet the main cognitive endpoint despite biomarker signals underscoring the translational gap between metabolic modulation and the complex nature of neurodegenerative processes